Form 4 for RPRX Royalty Pharma plc
Accepted 2025-11-07 00:00:00 ET · period of report 2025-11-05 · accession 0001507678-25-000010 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-07 | 2025-11-05 | RPRX | Legorreta Pablo G. | CEO, COB, Dir | A - Grant | $0.00 | +36.6K | 941.0K | +4% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Ordinary Shares | 2025-11-05 | A | A | 36,559 | $0.00 | 940,955 | D | — | — | (F1) Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards. |